Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

FFTIK
91818
TICKS
83265
concentration (8 mg q.i.d.): 72 to 184 ng/mL Pediatric patients (3-10 years) reach peak concentration at
approximately 2.4 hours.(5)
Reference Values:
Peak: 110-520 ng/mL
Trough: 5-35 ng/mL
Clinical References: 1. Product information: Gabitril Filmtab, tiagabine hydrochloride. Abbott
Laboratories, North Chicago, IL, 1997 2. So EL, Wolff D, Graves N, et al: Pharmacokinetics of
tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res
1995;22:221-226 3. Benedetti MS: Enzyme induction and inhibition by new antiepileptic drugs: a
review of human studies. Fundam Clin Pharmacol 2000;14:301-319 4. Perucca E: The clinical
pharmacokinetics of the new antiepileptic drugs. Epilepsia 1999;40:S7-S13 5. Gustavson LE, Soellner
SW, Granneman GR, et al: A single-dose study to define tiagabine pharmacokinetics in pediatric
patients with complex partial seizures. Neurology 1997;48:1032-1037 6. Cato A, Gustavson LE,
El-Shourbay, Kelly EZ: Effect of renal impairment on the pharmacokinetics and tolerability of
tiagabine. Epilepsia 1998;39:43-47 7. Wiley Cl, Enger RJ, Charlson JC, Moyer TP: Unpublished Mayo
information 8. Thompson MS, Groes L, Agerse H, Kruse T: Lack of pharmacokinetic interaction
between tiagabine and erythromycin. J Clin Pharmacol 1998;38:1051-1056
Tick Analysis and Identification by PCR B. burgdorferi
Reference Values:
Negative
Test Performed By: IMUGEN Reference Diagnostic Division
315 Norwood Park South
Norwood, MA 02062
Tick-Borne Disease Antibodies Panel, Serum
Clinical Information: In North America, ticks are the primary vectors of infectious diseases.(1)
Worldwide, ticks rank second only to mosquitoes in disease transmission. In the United States,
tick-borne diseases include Lyme disease, Rocky Mountain spotted fever, human monocytic and
granulocytic ehrlichiosis, babesiosis, tularemia, relapsing fever, and Colorado tick fever. Symptoms of
the various tick-vectored diseases range from mild to life-threatening. Early symptoms, which include
fever, aches, and malaise, do not aid in distinguishing the various diseases. Because early treatment can
minimize or eliminate the risk of severe disease, early detection is essential, yet patients may not have
developed distinctive symptoms to help in the differential diagnosis. A tick-borne panel can assist in
identifying the pathogen, allowing treatment to be initiated. For information on the specific diseases,
please see the individual unit codes.
Useful For: Evaluation of the most common tick-borne diseases found in the United States, including
Lyme disease, human monocytic and granulocytic ehrlichiosis, and babesiosis Evaluation of patients
with a history of, or suspected, tick exposure who are presenting with fever, myalgia, headache, nausea,
and other nonspecific symptoms
Interpretation: See Individual Unit Codes
Reference Values:
Ehrlichia chaffeensis (HME) ANTIBODY, IgG